Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Concentrix Corp.’s stock clocked out at $55.25, down -3.98% from its previous closing price of $57.54. In other words, the price has decreased by -$3.98 from its previous closing price. On the day, 0.51 million shares were traded. CNXC stock price reached its highest trading level at $58.315 during the session, while it also had its lowest trading level at $55.2.
Ratios:
To gain a deeper understanding of CNXC’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.04. For the most recent quarter (mrq), Quick Ratio is recorded 1.56 and its Current Ratio is at 1.56. In the meantime, Its Debt-to-Equity ratio is 1.44 whereas as Long-Term Debt/Eq ratio is at 1.39.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 27, 2024, Downgraded its rating to Underperform and sets its target price to $60 from $85 previously.
On September 06, 2023, Redburn Atlantic started tracking the stock assigning a Neutral rating and target price of $70.
On August 24, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $120.Scotiabank initiated its Sector Outperform rating on August 24, 2023, with a $120 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 03 ’24 when Fogarty Jane bought 400 shares for $61.04 per share. The transaction valued at 24,416 led to the insider holds 10,492 shares of the business.
Hayley Kathryn bought 379 shares of CNXC for $25,000 on Apr 01 ’24. The Director now owns 2,534 shares after completing the transaction at $65.96 per share. On Jan 30 ’24, another insider, Fogarty Jane, who serves as the EVP, Legal of the company, bought 200 shares for $89.27 each. As a result, the insider paid 17,853 and bolstered with 5,388 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNXC now has a Market Capitalization of 3646052352 and an Enterprise Value of 9343544320. As of this moment, Concentrix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.38, and their Forward P/E ratio for the next fiscal year is 4.27. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.46 while its Price-to-Book (P/B) ratio in mrq is 0.88. Its current Enterprise Value per Revenue stands at 1.186 whereas that against EBITDA is 7.547.
Stock Price History:
Over the past 52 weeks, CNXC has reached a high of $110.98, while it has fallen to a 52-week low of $56.81. The 50-Day Moving Average of the stock is -20.70%, while the 200-Day Moving Average is calculated to be -31.71%.
Shares Statistics:
It appears that CNXC traded 604.12K shares on average per day over the past three months and 683510 shares per day over the past ten days. A total of 65.73M shares are outstanding, with a floating share count of 47.36M. Insiders hold about 28.24% of the company’s shares, while institutions hold 66.12% stake in the company. Shares short for CNXC as of 1711584000 were 2173576 with a Short Ratio of 3.60, compared to 1709164800 on 2090410. Therefore, it implies a Short% of Shares Outstanding of 2173576 and a Short% of Float of 4.61.
Dividends & Splits
With its trailing 12-month dividend rate of 1.155, CNXC has a forward annual dividend rate of 1.16.
Earnings Estimates
The dynamic stock of Concentrix Corp. (CNXC) is currently attracting attention from ChromaDex Corporation analysts actively involved in rating its market status.The consensus estimate for the next quarter is $72.00, with high estimates of $1.50 and low estimates of $55.25.
Analysts are recommending an EPS of between $Consumer Cyclical and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
